TGR-1202 (sulfate)

TGR-1202 (sulfate) Suppliers list
Company Name: SPIRO PHARMA  
Tel:
Email: eric_feng1954@126.com
Company Name: TargetMol Chemicals Inc.  
Tel: 15002134094
Email: marketing@targetmol.cn
Company Name: TargetMol Chemicals Inc.  
Tel: 13564774135
Email: marketing@targetmol.com

TGR-1202 (sulfate) manufacturers

TGR-1202 (sulfate) Basic information
Product Name:TGR-1202 (sulfate)
Synonyms:TGR-1202 (sulfate);FGHFSOLOVRUJND-NTISSMGPSA-N;Umbralisib sulfate;RP-5264 sulfate|||TGR-1202 sulfate|||RP-5264 sulfate
CAS:1532533-75-7
MF:C31H26F3N5O7S
MW:669.63
EINECS:
Product Categories:
Mol File:1532533-75-7.mol
TGR-1202 (sulfate) Structure
TGR-1202 (sulfate) Chemical Properties
Safety Information
MSDS Information
TGR-1202 (sulfate) Usage And Synthesis
UsesUmbralisib (TGR-1202) sulfate is an orally active, potent and selective dual PI3Kδ and casein kinase-1-ε (CK1ε) inhibitor, with EC50 of 22.2 nM and 6.0 μM, respectively. Umbralisib sulfate exhibits unique immunomodulatory effects on chronic lymphocytic leukemia (CLL) T cells. Umbralisib sulfate can be used for haematological malignancies reseach[1][2][3][4].
in vivo

Umbralisib sulfate (150 mg/kg, daily p.o.) significantly shrinks the tumors by day 25 in a subcutaneous xenograft model of T-cell acute lymphoblastic leukemia (T-ALL) in NOD/SCID mice using the MOLT-4 cell line[4].

IC 50PI3Kδ: 6.2 (Kd); PI3Kγ: 1400 (Kd); PI3Kα: >10000 (Kd); PI3Kβ: >10000 (Kd)
References[1] Maharaj K, et al. The dual PI3Kδ/CK1ε inhibitor umbralisib exhibits unique immunomodulatory effects on CLL T cells. Blood Adv. 2020 Jul 14;4(13):3072-3084. DOI:10.1182/bloodadvances.2020001800
[2] Burris HA 3rd, et al. Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study. Lancet Oncol. 2018 Apr;19(4):486-496. DOI:10.1016/S1470-2045(18)30082-2
[3] Swaroop Vakkalankaa, et al. Inhibition of PI3Kδ kinase by a selective, small molecule inhibitor suppresses B-cell proliferation and leukemic cell growth.
[4] Deng C, et al. Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kδ and CK1ε in hematological malignancies. Blood. 2017 Jan 5;129(1):88-99. DOI:10.1182/blood-2016-08-731240
TGR-1202 (sulfate) Preparation Products And Raw materials
Tag:TGR-1202 (sulfate)(1532533-75-7) Related Product Information
TGR-1202 (hydrochloride) TGR-1202 (sulfate) TGR-1202 (R-enantiomer) Umbralisib TGR-1202 (4-Methylbenzenesulfonate) NVP-BEZ 235